Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) announced today that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026. Goettler stepped down in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
Board Chair Expresses Gratitude
“We thank Michael for his valued service and wish him the best in his new role,” said John A. Paulson, Chairperson of the Bausch Health Board of Directors. The company emphasized that Goettler’s resignation was not the result of any disagreement with Bausch Health on any matter relating to the company’s operations, policies, or practices.
About Bausch Health
Bausch Health Companies Inc. is a global, diversified pharmaceutical company focused on delivering better healthcare outcomes. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health through its controlling interest in Bausch + Lomb Corporation. The company aims to be a globally integrated healthcare company trusted by patients, healthcare professionals, employees, and investors.
For more information, visit www.bauschhealth.com or connect on LinkedIn. Investor inquiries can be directed to Garen Sarafin at ir@bauschhealth.com or (877) 281-6642. Media inquiries can be directed to Katie Savastano at corporate.communications@bauschhealth.com or (908) 569-3692.
